Chowdhary S, Vaile J C, Fletcher J, Ross H F, Coote J H, Townend J N
Department of Cardiovascular Medicine, University of Birmingham, UK.
Hypertension. 2000 Aug;36(2):264-9. doi: 10.1161/01.hyp.36.2.264.
Cardiac autonomic control is of prognostic significance in cardiac disease, yet the control mechanisms of this system remain poorly defined. Animal data suggest that nitric oxide (NO) modulates cardiac autonomic control. We investigated the influence of NO on the baroreflex control of heart rate in healthy human subjects. In 26 healthy male volunteers (mean age, 23+/-5 years), we measured heart rate variability and baroreflex sensitivity during inhibition of endogenous NO production with N(G)-monomethyl-L-arginine (L-NMMA) (3 mg/kg per hour) and during exogenous NO donation with sodium nitroprusside (1 to 3 mg/h). Increases from baseline (Delta) in high-frequency (HF) indexes of heart rate variability were smaller with L-NMMA in comparison to an equipressor dose of the control vasoconstrictor phenylephrine (12 to 42 microg/kg per hour): Deltaroot mean square of successive RR interval differences (DeltaRMSSD)=23+/-32 versus 51+/-48 ms (P<0.002); Deltapercentage of successive RR interval differences >50 ms (DeltapNN50)=5+/-15% versus 14+/-12% (P<0.05); and DeltaHF normalized power=-2+/-7 versus 9+/-8 normalized units (P<0.01), respectively. Relative preservation of these indexes was observed during unloading of the baroreflex with sodium nitroprusside compared with a matched fall in blood pressure produced by a control vasodilator, hydralazine (9 to 18 mg/h): DeltaRMSSD=-8+/-8 versus -24+/-15 ms (P<0.001); DeltapNN50=-6+/-11% versus -15+/-19% (P<0.01); DeltaHF normalized power=-7+/-13 versus -13+/-11 normalized units (P<0.05), respectively. The change in cross-spectral alpha-index calculated as the square root of the ratio of RR interval power to systolic spectral power in the HF band (although not alpha-index calculated in the same way for the low-frequency bands or baroreflex sensitivity assessed by the phenylephrine bolus method) was attenuated with L-NMMA compared with phenylephrine (Delta=4+/-8 versus 14+/-15 ms/mm Hg, respectively; P<0.02) and with sodium nitroprusside compared with hydralazine (Delta=-7+/-6 and -9+/-7 ms/mm Hg, respectively; P<0.05). In conclusion, these data demonstrate that NO augments cardiac vagal control in humans.
心脏自主神经控制在心脏疾病中具有预后意义,但该系统的控制机制仍不清楚。动物数据表明,一氧化氮(NO)可调节心脏自主神经控制。我们研究了NO对健康人类受试者心率压力反射控制的影响。在26名健康男性志愿者(平均年龄23±5岁)中,我们测量了在使用N(G)-单甲基-L-精氨酸(L-NMMA)(每小时3mg/kg)抑制内源性NO生成期间以及使用硝普钠(1至3mg/h)进行外源性NO供体期间的心率变异性和压力反射敏感性。与等剂量的对照血管收缩剂去氧肾上腺素(每小时12至42μg/kg)相比,L-NMMA使心率变异性高频(HF)指标相对于基线(Delta)的增加更小:连续RR间期差值的均方根(DeltaRMSSD)=23±32对51±48ms(P<0.002);连续RR间期差值>50ms的百分比(DeltapNN50)=5±15%对14±12%(P<0.05);以及DeltaHF归一化功率=-2±7对9±8归一化单位(P<0.01)。与对照血管扩张剂肼屈嗪(9至18mg/h)引起的血压匹配下降相比,在使用硝普钠使压力反射卸载期间观察到这些指标的相对保留:DeltaRMSSD=-8±8对-24±15ms(P<0.001);DeltapNN50=-6±11%对-15±19%(P<0.01);DeltaHF归一化功率=-7±13对-13±11归一化单位(P<0.05)。以HF频段RR间期功率与收缩期频谱功率之比的平方根计算的交叉谱α指数的变化(尽管不是以相同方式计算的低频段α指数或通过去氧肾上腺素推注法评估的压力反射敏感性)与去氧肾上腺素相比,L-NMMA使其减弱(Delta分别为4±8对14±15ms/mm Hg;P<0.02),与肼屈嗪相比,硝普钠使其减弱(Delta分别为-7±6和-9±7ms/mm Hg;P<0.05)。总之,这些数据表明NO增强了人类心脏迷走神经控制。